Our Mission
About
- Our team
- Info
- David Wallace Bio
  David Wallace
  
  Founder & CEO of MPN Cancer Connection and PV Reporter | Patient Advocate
  When David was diagnosed with PV in 2009, at the age of 47, he soon learned there was limited and often conflicting information available on Myeloproliferative Neoplasms (MPNs). He also realized early on in his diagnosis, the importance of advocating for himself to best manage his polycythemia vera (PV). David was grateful for the early support and guidance of fellow MPN patients on his journey and wanted a way to give back to the MPN community. With a professional background in business administration and sociology, David has a passion for finding solutions and helping others. In 2013, David used his skill set to create PV Reporter, a comprehensive patient-focused website for MPNs. David refers to his site as a hub for patients to begin to research their cancer. Whether a patient, caregiver or healthcare provider, PV Reporter offers visitors a wealth of educational resources, patient stories, articles, and the latest news on the treatment for MPNs, helping MPN patients and their caregivers stay informed, connected and empowered. In 2015, along with the help of others, David founded a non-profit MPN Cancer Connection (MPN-CC), a patient-led 501©3 formed to create awareness that MPN patients are “cancer patients” and should have complete access to local and national programs and benefits. David’s philosophy is to educate patients to become their own advocates so that they can make informed decisions on their treatment. David’s dedication to the MPN community is further evidenced through his work and awards:
  - Selected to endorse 2018 NCCN guidelines for MPN patients by MPN Cancer Connection
  - Selected to represent the United States as a patient advocate by MPNs Advocate Network International Conference 2016-2019
  - Recipient of MPN Hero Award 2016
  - Published in MD Anderson Cancer Center MPN Focus Newsletter Fall 2016
  - Appearance on “The Doctors” TV show in 2015 to promote MPN awareness
  - Awarded Press Credentials for American Society of Hematology Conference 2014-2019
  - Contributor to Patient Power MPN educational videos
  David lives in Charlotte, North Carolina. When he’s not working, David enjoys spending time with family, listening to live music, attending outdoor festivals, watching the Carolina Panthers, riding his motorcycle, traveling and of course having his beloved Aussiedoodle Bailey by his side.
Resources
- Partners
- Groups
Our Vision
Donate
- Corporate Sponsors
Blog
Contact

Donate

myelofibrosis

February 1, 2018

Published by mpncancer at February 1, 2018

Categories

Imago BioSciences gets FDA Approval of IND Application for Treatment of Myelofibrosis, IMG-7289 in Clinical Trials

Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their […]

June 29, 2017

Published by mpncancer at June 29, 2017

Categories

Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and Ruxolitinib

This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of […]

June 5, 2017

Immunofluorescence of single human cell stained grown in tissue culture, stained with multiple antibodies and visualized via confocal microscopy

Published by David Wallace at June 5, 2017

Categories

A New Therapeutic Target for Myelofibrosis is cause for Gli

Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone […]

August 30, 2016